An Investigation of rhTPO With Different Frequencies in the Management of ITP

PHASE3CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Recombinant Human Thrombopoietin (rhTPO)

rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days

Trial Locations (1)

250012

Qilu Hospital, Shandong University, Jinan

All Listed Sponsors
collaborator

The First Affiliated Hospital of Dalian Medical University

OTHER

collaborator

Shandong Provincial Hospital

OTHER_GOV

lead

Shandong University

OTHER

NCT02139501 - An Investigation of rhTPO With Different Frequencies in the Management of ITP | Biotech Hunter | Biotech Hunter